Spinal cord injury patients get first shot at novel cell delivery device

NCT ID NCT06841770

Recruiting now Disease control Sponsor: Lineage Cell Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a new device designed to deliver OPC1 cells directly into the spinal cord of people with traumatic spinal cord injuries. The study will enroll 10 participants with either recent or chronic injuries. The main goal is to see if the device and injection procedure are safe, while also looking for signs that the cells might help restore function.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: OPC1 cells (oligodendrocyte progenitor cells)
What this could lead to: If successful, this could point toward a treatment that helps restore function and improve quality of life for people with spinal cord injuries.
What could go wrong: This is a very early Phase 1 trial with only 10 participants, so it is primarily testing safety. The treatment also requires immunosuppression, which carries risks, and it may not improve function.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SPINAL CORD INJURY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Bronchiolitis Obliterans Syndrome palsy quadriplegia spinal cord injury

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SPINAL CORD INJURY SPINAL CORD INJURY CERVICAL SPINAL CORD INJURY THORACIC SPINAL CORD INJURY, ACUTE SPINAL CORD INJURY, CHRONIC

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Rancho Research Institue
NOT_YET_RECRUITING

Downey, California, 90242, United States

Contact Email: •••••@•••••
University of California, San Diego
RECRUITING

La Jolla, California, 92037, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.